Literature DB >> 1658377

Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.

A H Davies1, R J Grand, F J Evans, A B Rickinson.   

Abstract

Exposure to the tiglian 12-O-tetradecanoylphorbol-13-acetate (TPA) represents one of the most efficient and widely used protocols for inducing Epstein-Barr virus (EBV)-infected cells from latent into lytic cycle. Since TPA is both a potent tumor promoter and a potent activator of the cellular protein kinase C (PKC), we sought to determine whether either of these activities was closely linked to EBV lytic cycle induction. A panel of TPA structural analogs, encompassing tiglians with different spectra of biological activities, was assayed on a number of EBV-positive B-lymphoid cell lines. Lytic cycle induction correlated with the capacity to activate PKC, not with tumor promoter status; some nonpromoting tiglians were as efficient as TPA in inducing lytic cycle antigen expression. We then sought more direct evidence for an involvement of PKC in the induction process. In initial experiments, 1-(5-isoquinolinyl sulphonyl)-2-methylpiperazine (H-7), the best available pharmacological inhibitor of PKC, completely blocked the induction of the lytic cycle by TPA and its active analogs. This is consistent with, but does not prove, a requirement for active PKC in the induction process, since H-7 targets PKC preferentially but also has some effects on other kinases. We therefore turned to the synthetic pseudosubstrate peptide PKC(19-36) as a means of specific PKC inhibition and to the closely related but inactive peptide PKC(19-Ser-25-36) as a control. Using the technique of scrape loading to deliver the peptides into cells of an adherent EBV-positive target line, we found that the pseudosubstrate peptide PKC(19-36) completely and specifically blocked tiglian-induced entry of the cells into the lytic cycle. The evidence both from TPA analogs and from enzyme inhibition studies therefore indicates that the pathway linking TPA treatment to lytic cycle induction involves active PKC. Interestingly, inhibition of PKC had no effect upon the spontaneous entry into lytic cycle which occurs in naturally productive cell lines, suggesting that spontaneous entry is signalled by another route.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658377      PMCID: PMC250778     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Activation of latent Epstein-Barr virus by antibody to human IgM.

Authors:  M G Tovey; G Lenoir; J Begon-Lours
Journal:  Nature       Date:  1978-11-16       Impact factor: 49.962

2.  TPA induction of Epstein-Barr virus early antigens in Raji cells is blocked by selective protein kinase-C inhibitors.

Authors:  J Lazdins; C Zompetta; S Grimaldi; G Barile; M Venanzoni; L Frati; A Faggioni
Journal:  Int J Cancer       Date:  1987-12-15       Impact factor: 7.396

Review 3.  Phorbol ester activation of the isotypes of protein kinase C from bovine and rat brain.

Authors:  F J Evans; P J Parker; A R Olivier; S Thomas; W J Ryves; A T Evans; P Gordge; P Sharma
Journal:  Biochem Soc Trans       Date:  1991-04       Impact factor: 5.407

Review 4.  The molecular heterogeneity of protein kinase C and its implications for cellular regulation.

Authors:  Y Nishizuka
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

Review 5.  Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases.

Authors:  U T Rüegg; G M Burgess
Journal:  Trends Pharmacol Sci       Date:  1989-06       Impact factor: 14.819

6.  Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.

Authors:  K Takada; Y Ono
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

7.  Activation of Epstein-Barr virus by 5-bromodeoxyuridine in "virus-free" human cells (complement-fixing antigen-immunofluorescence-leukocytes).

Authors:  P Gerber
Journal:  Proc Natl Acad Sci U S A       Date:  1972-01       Impact factor: 11.205

8.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

9.  Hybridization of Burkitt lymphoblastoid cells.

Authors:  R Glaser; F J O'Neill
Journal:  Science       Date:  1972-06-16       Impact factor: 47.728

10.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

View more
  28 in total

1.  Functional analysis of the CD4(+) T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression.

Authors:  Z Fu; M J Cannon
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Reactivation of the Epstein-Barr virus from viral latency by an S-adenosylhomocysteine hydrolase/14-3-3 zeta/PLA2-dependent pathway.

Authors:  Diana Maas; Claudine Maret; Lars Schaade; Simone Scheithauer; Klaus Ritter; Michael Kleines
Journal:  Med Microbiol Immunol       Date:  2006-06-21       Impact factor: 3.402

4.  Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA.

Authors:  C Meyers; T J Mayer; M A Ozbun
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

5.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

6.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  Role of RNF4 in the ubiquitination of Rta of Epstein-Barr virus.

Authors:  Ya-Chun Yang; Yushi Yoshikai; Shih-Wei Hsu; Hisato Saitoh; Li-Kwan Chang
Journal:  J Biol Chem       Date:  2013-03-15       Impact factor: 5.157

8.  Differential effect of TPA on cell growth and Epstein-Barr virus reactivation in epithelial cell lines derived from gastric tissues and B cell line Raji.

Authors:  M Kanamori; M Tajima; Y Satoh; Y Hoshikawa; Y Miyazawa; K Okinaga; T Kurata; T Sairenji
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

9.  Epstein-Barr virus latently infected cells are selectively deleted in simulated-microgravity cultures.

Authors:  J P Long; J H Hughes
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-04       Impact factor: 2.416

10.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.